Virax names new managing director
Virax Holdings (ASX:VHL) has selected seasoned biotech executive Dr Rob Crombie to become its new managing director.
Crombie will take the reins of Virax on 16 June. He will be paid an annual salary of $300,000, as well as performance-based bonuses worth up to 20% of this salary.
Crombie played a key role in taking Arana Therapeutics from IPO to a $318 million sale. He has also held senior management positions at EvoGenix and is now a specialist consultant to start-up companies.
Virax Executive Chairman Dr Wayne Millen said Crombie has “an exemplary [commercial and scientific] background, bringing valuable doctoral qualifications in molecular oncology and deep commercial biotechnology experience particularly in partnerships, M&A and licensing agreements with global pharmaceutical companies”.
In his new role, Crombie said he plans to concentrate on taking Virax’s in-licensed oncology assets into clinical trials as quickly as possible.
Virax recently arranged to acquire Pathway Oncology, which has an exclusive worldwide licence to a cancer drug developed at Yale University and the Moffitt Cancer Center.
Virax Holdings (ASX:VRX) shares were trading unchanged at $0.008 as of around 12.30 pm on Thursday.
Could this 'virus-tearing' plastic film protect hospital equipment?
A thin plastic film that tears apart viruses on contact could help protect high-touch hospital...
'Smart bandage' heals and monitors simultaneously
By embedding tiny, multi-functional nanomaterials into hydrogel dressing, this smart bandage...
This AI model judges molecular stability on its own, researchers say
Korean researchers have developed an artificial intelligence model that, they say, understands...
